{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:58:44Z","timestamp":1793764724146,"version":"4.6.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T00:00:00Z","timestamp":1676592000000},"content-version":"am","delay-in-days":353,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5T32GM007309"],"award-info":[{"award-number":["5T32GM007309"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["F30CA224588"],"award-info":[{"award-number":["F30CA224588"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["F30HL142131"],"award-info":[{"award-number":["F30HL142131"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32GM007753"],"award-info":[{"award-number":["T32GM007753"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jaad.2021.03.094","type":"journal-article","created":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T11:35:15Z","timestamp":1617363315000},"page":"563-572","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":102,"title":["Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis"],"prefix":"10.1016","volume":"86","author":[{"given":"Shannon","family":"Wongvibulsin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vartan","family":"Pahalyants","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Kalinich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun-Hsing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feicheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn G.","family":"Kwatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yevgeniy R.","family":"Semenov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.jaad.2021.03.094_bib1","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jaad.2021.03.094_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.jaad.2021.03.094_bib3","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"CME Part II: immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2021.03.094_bib4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ctrv.2017.05.003","article-title":"Combined immune checkpoint blockade (anti-PD-1\/anti-CTLA-4): evaluation and management of adverse drug reactions","volume":"57","author":"Hassel","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.jaad.2021.03.094_bib5","doi-asserted-by":"crossref","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.jaad.2021.03.094_bib6","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.03.094_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.jaad.2021.03.094_bib8","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3899\/jrheum.190084","article-title":"Immune-related adverse events associated with cancer immunotherapy: a review for the practicing rheumatologist","volume":"47","author":"Jamal","year":"2020","journal-title":"J Rheumatol"},{"issue":"17","key":"10.1016\/j.jaad.2021.03.094_bib9","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.jaad.2021.03.094_bib10","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1200\/JCO.18.02141","article-title":"Treatment outcomes of immune-related cutaneous adverse events","volume":"37","author":"Phillips","year":"2019","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jaad.2021.03.094_bib11","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.2217\/imt-2016-0074","article-title":"Dermatologic adverse events of checkpoint inhibitors: what an oncologist should know","volume":"8","author":"Habre","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jaad.2021.03.094_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/1758834017751634","article-title":"Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management","volume":"10","author":"Shen","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.jaad.2021.03.094_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1758835918764628","article-title":"Clinical assessment of immune-related adverse events","volume":"10","author":"Sosa","year":"2018","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"10.1016\/j.jaad.2021.03.094_bib14","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/CCO.0000000000000290","article-title":"Dermatologic complications of anti-PD-1\/PD-L1 immune checkpoint antibodies","volume":"28","author":"Sibaud","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.jaad.2021.03.094_bib15","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor","volume":"60","author":"Belum","year":"2016","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.jaad.2021.03.094_bib16","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/cncr.27969","article-title":"Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma","volume":"119","author":"Weber","year":"2013","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.jaad.2021.03.094_bib17","doi-asserted-by":"crossref","first-page":"405","DOI":"10.5301\/tj.5000625","article-title":"Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity","volume":"103","author":"Inno","year":"2017","journal-title":"Tumori"},{"issue":"2","key":"10.1016\/j.jaad.2021.03.094_bib18","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/cup.12858","article-title":"Diverse types of dermatologic toxicities from immune checkpoint blockade therapy","volume":"44","author":"Curry","year":"2017","journal-title":"J Cutan Pathol"},{"issue":"21","key":"10.1016\/j.jaad.2021.03.094_bib19","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jaad.2021.03.094_bib20","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/jamadermatol.2018.1912","article-title":"Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1 inhibitor therapy","volume":"154","author":"Wang","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.03.094_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-019-0645-6","article-title":"Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance","volume":"7","author":"Couey","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.jaad.2021.03.094_bib22","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/ijd.13984","article-title":"A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors","volume":"57","author":"Lopez","year":"2018","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2021.03.094_bib23","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.jaad.2021.03.094_bib24","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/cpt.1597","article-title":"Autoimmune effects of lung cancer immunotherapy revealed by data-driven analysis on a nationwide cohort","volume":"107","author":"Yang","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.jaad.2021.03.094_bib25","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"1","key":"10.1016\/j.jaad.2021.03.094_bib26","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1631\/jzus.B1300109","article-title":"Charlson comorbidity index helps predict the risk of mortality for patients with type 2 diabetic nephropathy","volume":"15","author":"Huang","year":"2014","journal-title":"J Zhejiang Univ Sci B"},{"issue":"2","key":"10.1016\/j.jaad.2021.03.094_bib27","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.currproblcancer.2016.12.001","article-title":"Cutaneous adverse effects of the immune checkpoint inhibitors","volume":"41","author":"Collins","year":"2017","journal-title":"Curr Probl Cancer"},{"issue":"2","key":"10.1016\/j.jaad.2021.03.094_bib28","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s12254-018-0416-y","article-title":"Management of adverse events related to checkpoint inhibition therapy","volume":"11","author":"Rudzki","year":"2018","journal-title":"Memo"},{"issue":"12","key":"10.1016\/j.jaad.2021.03.094_bib29","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.jaad.2021.03.094_bib30","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1080\/15569527.2019.1685536","article-title":"Immune-related dermatologic toxicities: to make a long story short","volume":"39","author":"Angelaki","year":"2020","journal-title":"Cutan Ocul Toxicol"},{"issue":"9","key":"10.1016\/j.jaad.2021.03.094_bib31","doi-asserted-by":"crossref","first-page":"e1911519","DOI":"10.1001\/jamanetworkopen.2019.11519","article-title":"Variation in the assessment of immune-related adverse event occurrence, grade, and timing in patients receiving immune checkpoint inhibitors","volume":"2","author":"Hsiehchen","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.jaad.2021.03.094_bib32","first-page":"1","article-title":"Nivolumab bullous pemphigoid: case description and literature review","volume":"9","author":"Anedda","year":"2019","journal-title":"J Clin Exp Pathol"},{"key":"10.1016\/j.jaad.2021.03.094_bib33","doi-asserted-by":"crossref","first-page":"9602540","DOI":"10.1155\/2018\/9602540","article-title":"Immune toxicity with checkpoint inhibition for metastatic melanoma: case series and clinical management","volume":"2018","author":"Lomax","year":"2018","journal-title":"J Skin Cancer"},{"issue":"10","key":"10.1016\/j.jaad.2021.03.094_bib34","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1097\/PAS.0000000000000900","article-title":"Cutaneous eruptions in patients receiving immune checkpoint blockade: clinicopathologic analysis of the non-lichenoid histologic pattern","volume":"41","author":"Kaunitz","year":"2017","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.jaad.2021.03.094_bib35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1590\/S0365-05962013000100001","article-title":"Paraneoplastic cutaneous manifestations: concepts and updates","volume":"88","author":"Silva","year":"2013","journal-title":"An Bras Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.03.094_bib36","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jdcr.2017.09.014","article-title":"Paraneoplastic psoriasis in a patient with prostate cancer","volume":"4","author":"Cadmus","year":"2018","journal-title":"JAAD Case Rep"},{"issue":"1","key":"10.1016\/j.jaad.2021.03.094_bib37","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1111\/ajd.13133","article-title":"Metastatic prostate cancer presenting as subacute cutaneous lupus erythematosus","volume":"61","author":"Phan","year":"2020","journal-title":"Australas J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.03.094_bib38","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jaad.2015.10.029","article-title":"Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort","volume":"74","author":"Hwang","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.03.094_bib39","first-page":"513","article-title":"Case report of multiple keratoacanthomas and squamous cell carcinomas in a patient eeceiving pembrolizumab","volume":"16","author":"Chaudhari","year":"2017","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.03.094_bib40","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2021.03.094_bib41","doi-asserted-by":"crossref","first-page":"102983","DOI":"10.1016\/j.critrevonc.2020.102983","article-title":"Patients with lung cancer undergoing immune checkpoint inhibitors: a meta-analysis of dermatological toxicities","volume":"152","author":"dos Santos Garrett","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"issue":"8","key":"10.1016\/j.jaad.2021.03.094_bib42","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamaoncol.2016.6749","article-title":"Feasibility assessment of patient reporting of symptomatic adverse events in multicenter cancer clinical trials","volume":"3","author":"Basch","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaad.2021.03.094_bib43","doi-asserted-by":"crossref","first-page":"174","DOI":"10.14694\/EdBook_AM.2012.32.79","article-title":"Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist","volume":"32","author":"Weber","year":"2012","journal-title":"Am Soc Clin Oncol Educ B"},{"issue":"6","key":"10.1016\/j.jaad.2021.03.094_bib44","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/bjd.19313","article-title":"Diagnostic and therapeutic differences between immune checkpoint inhibitor-induced and idiopathic bullous pemphigoid: a cross-sectional study","volume":"183","author":"Molina","year":"2020","journal-title":"Br J Dermatol"},{"issue":"26","key":"10.1016\/j.jaad.2021.03.094_bib45","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jaad.2021.03.094_bib46","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962221006617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962221006617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:01:11Z","timestamp":1759273271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962221006617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0190962221006617"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2021.03.094","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2021.03.094","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}